Cerity Partners
RARE icon

Cerity Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cerity Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$668K Buy
31,892
+16,214
+103% +$365K ﹤0.01% 2106
2025
Q4 		$361K Buy
+15,678
New +$516K ﹤0.01% 2295
2024
Q4 		– Sell
-31,919
Closed -$1.77M – 2564
2024
Q3 		$1.77M Buy
+31,919
New +$1.63M ﹤0.01% 1147

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Cerity Partners's RARE Position: Q1 2026 in Review

Cerity Partners increased its Ultragenyx Pharmaceutical (RARE) stake by 103% in Q1 2026, buying an estimated $365K and bringing the position to 31,892 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

Cerity Partners first reported a position in RARE in Q3 2024 and has held it in 3 quarters since. The position peaked at $1.77M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Cerity Partners held 31,892 shares of Ultragenyx Pharmaceutical worth $668K as of Q1 2026.
  • Cerity Partners bought 16,214 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $365K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2106 holding.
  • Cerity Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and has held it in 3 quarters since.
  • Cerity Partners's Ultragenyx Pharmaceutical position peaked at $1.77M in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.